中国新药与临床杂志
中國新藥與臨床雜誌
중국신약여림상잡지
CHINESE JOURNAL OF NEW DRUGS AND CLINICAL REMEDIES
2001年
2期
125-126
,共2页
杨金龙%夏子禹%游龙英%郑水根%吕萍%张小青
楊金龍%夏子禹%遊龍英%鄭水根%呂萍%張小青
양금룡%하자우%유룡영%정수근%려평%장소청
卡尼汀%人病毒性肝炎%药物疗法
卡尼汀%人病毒性肝炎%藥物療法
잡니정%인병독성간염%약물요법
目的:评估复方卡尼汀治疗慢性病毒性肝炎的作用。方法:91例慢性病毒性肝炎病人分为2组。对照组30例(男性20例,女性10例,年龄41 a± s 17 a),给予甘草酸单铵80 mL加入10%葡萄糖注射液500 mL中iv,gtt,qd,疗程30 d。治疗组61例(男性49例,女性12例,年龄40 a±13 a),在甘草酸单铵治疗基础上,给予复方卡尼汀2支加入10%葡萄糖注射液500 mL中iv,gtt,qd,疗程30 d。结果:治疗组对改善病人乏力、纳差、降低ALT的总有效率分别为93%,100%,92%,均明显优于对照组75%,84%,70%(P<0.05)。对2组部分病人治疗6 mo时的随访表明治疗组的ALT复常率为83%,明显高于对照组54%(P<0.05),无明显不良反应。结论:复方卡尼汀是一种有效的治疗慢性病毒性肝炎的药物。
目的:評估複方卡尼汀治療慢性病毒性肝炎的作用。方法:91例慢性病毒性肝炎病人分為2組。對照組30例(男性20例,女性10例,年齡41 a± s 17 a),給予甘草痠單銨80 mL加入10%葡萄糖註射液500 mL中iv,gtt,qd,療程30 d。治療組61例(男性49例,女性12例,年齡40 a±13 a),在甘草痠單銨治療基礎上,給予複方卡尼汀2支加入10%葡萄糖註射液500 mL中iv,gtt,qd,療程30 d。結果:治療組對改善病人乏力、納差、降低ALT的總有效率分彆為93%,100%,92%,均明顯優于對照組75%,84%,70%(P<0.05)。對2組部分病人治療6 mo時的隨訪錶明治療組的ALT複常率為83%,明顯高于對照組54%(P<0.05),無明顯不良反應。結論:複方卡尼汀是一種有效的治療慢性病毒性肝炎的藥物。
목적:평고복방잡니정치료만성병독성간염적작용。방법:91례만성병독성간염병인분위2조。대조조30례(남성20례,녀성10례,년령41 a± s 17 a),급여감초산단안80 mL가입10%포도당주사액500 mL중iv,gtt,qd,료정30 d。치료조61례(남성49례,녀성12례,년령40 a±13 a),재감초산단안치료기출상,급여복방잡니정2지가입10%포도당주사액500 mL중iv,gtt,qd,료정30 d。결과:치료조대개선병인핍력、납차、강저ALT적총유효솔분별위93%,100%,92%,균명현우우대조조75%,84%,70%(P<0.05)。대2조부분병인치료6 mo시적수방표명치료조적ALT복상솔위83%,명현고우대조조54%(P<0.05),무명현불량반응。결론:복방잡니정시일충유효적치료만성병독성간염적약물。
AIM: To observe the clinical effect of compound carnitine in treating chronic viral hepatitis. METHODS: Ninety-one patients with chronic viral hepatitis were randomly divided into 2 groups. Control group of 30 patients (M 20,F 10; age 41 a± s 17 a) received compound glycynhizin 80 mL in 10% glucose injection 500 mL, iv, gtt, qd for 30 d. The treatment group of 61 patients(M 49,F 12; age 40 a±13 a) received compound carnitine 2 ampules. in 10% glucose injection 500 mL, iv, gtt, qd for 30 d, besides the compound glycyrrhizin therapy. RESULTS: The total response rate of improving the patients' fatigue, anorexia and normalization of ALT in the treatment group were 93%, 100% and 92% respectively, which was more excellent than that (75%, 84% and 70% respectively) in the control group (P<0.05). At the end of 6 mo treatment, the rate of the normalization of ALT in the treatment group was 83%, which was much higher than that (54%) in the control group (P<0.05), according to the statistics of the partial patients in both groups. No obvious adverse reaction was observed.CONCLUSION: Compound carnitine is an effective drug in treating chronic viral hepatitis.